← Leaderboards
Joseph T Hanlon
University Of Pittsburgh At Pittsburgh
$2,963,613
Attributed
$2,963,613
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $557.4K · FY2006–19$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$2,963,613 · 5
By mechanism
R01$1,251,857 · 2
P30$1,008,539 · 1
K07$461,217 · 1
R56$242,000 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Milos Hauskrecht$3,805,461
- Gilles Clermont$11,470,744
- Abhinav Humar$1,832,806
- Khaled A Abdel-Kader$2,565,864
- Juleen Rodakowski$3,156,284
Others in their field
Top investigators on “Area”
- David Heimbrook · Leidos Biomedical Research, Inc.$781,609,239
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
Research focus
AreaFundingAgingElderlyFuturePharmaceutical PreparationsDoctor Of PhilosophyInstitutesPharmacy FacilityResearch PersonnelGeriatricsGrantFunctional StatusProgramsMultidisciplinaryMentorsMemberEpidemiologyHealthcare SystemsDosageFacultyAwardLeadershipMeetings
Grant awards (17)
Pilot/Experimental Studies Core$218,261
P30 · FY2019 · AG · contact PI
Pilot/Experimental Studies Core$223,646
P30 · FY2018 · AG · contact PI
Pilot/Experimental Studies Core$192,310
P30 · FY2017 · AG · contact PI
Pilot/Experimental Studies Core$198,510
P30 · FY2016 · AG · contact PI
Pilot/Experimental Studies Core$175,812
P30 · FY2015 · AG · contact PI
UPITT Program for Pharmaceutical Outcomes Research in Aging$93,392
K07 · FY2013 · AG · contact PI
Longitudinal Impact of Antihypertensive Polypharmacy on Geriatric Syndromes$266,875
R01 · FY2012 · AG · contact PI
UPITT Program for Pharmaceutical Outcomes Research in Aging$93,392
K07 · FY2012 · AG · contact PI
UPITT Program for Pharmaceutical Outcomes Research in Aging$93,392
K07 · FY2011 · AG · contact PI
Longitudinal Impact of Antihypertensive Polypharmacy on Geriatric Syndromes$242,000
R56 · FY2010 · AG · contact PI
Racial Disparities in Older Adults: Impact of Medicare Part D$223,905
R01 · FY2010 · AG · contact PI
UPITT Program for Pharmaceutical Outcomes Research in Aging$91,459
K07 · FY2010 · AG · contact PI
Racial Disparities in Older Adults: Impact of Medicare Part D$227,250
R01 · FY2009 · AG · contact PI
UPITT Program for Pharmaceutical Outcomes Research in Aging$89,582
K07 · FY2009 · AG · contact PI
Longitudinal Impact of CNS Polypharmacy on Geriatric Sy*$173,813
R01 · FY2008 · AG · contact PI
Longitudinal Impact of CNS Polypharmacy on Geriatric Syndromes$177,359
R01 · FY2007 · AG · contact PI
Longitudinal Impact of CNS Polypharmacy on Geriatric Syn$182,655
R01 · FY2006 · AG · contact PI